# Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm – 1:00 pm

Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH,
Chief, Office of Viral Hepatitis Prevention
California Department of Public Health





#### **Disclosures**

The speakers do not have relevant financial relationships with commercial interests.





#### **Overview**

- Why hepatitis C?
- Epidemiology of hepatitis C in California
- Hepatitis C transmission, testing
- Role of Hubs & Spokes in reducing the hepatitis C disease burden



# Why Hepatitis C?

- SAMHSA/CDC/U.S. Preventive Services Task Force HCV Testing Recommendations:
  - Persons born during 1945-1965 (one-time)
  - People who have ever injected drugs (routine)<sup>1</sup>
- DHCS Hub & Spokes Grant Requirements:

"Hubs need to perform HIV and Hepatitis C virus (HCV) testing on all individuals who enter treatment. Funds can be utilized for testing only if the costs are not already covered by other sources."<sup>2</sup>



- 1. Source: SAMHSA HCV Screening Advisory, 2015.
- 2. DHCS Opioid State Targeted Response (STR) Application

### Hepatitis C Virus: What Is It?

HOW LONG DOES HCV LIVE OUTSIDE THE BODY?










- Bloodborne virus that enters the body, replicates in the liver
- Can be cured in 8-12 wks.!
- Leading cause of liver transplant
- Most unaware of their infection





# **Sharing Injection Equipment =** #1 HCV Transmission Route



### **Other Blood Transmission Routes**

- Tattooing in prisons
- Mother-to-child at birth
  - ~ 5% risk; 20% if HIV coinfected



 Bloodborne exposures in health care settings (e.g., needlesticks). Risk from needlestick:

<u>HIV</u>	<u>HCV</u>	<u>HBV</u>
0.3%	2%	30%

- aring razors)
- Household transmission (e.g., sharing razors)
- Intranasal drug use → theoretical risk




### **HCV Transmission: Sexual**

- Low risk among heterosexual, long-term, monogamous, HCV +/- partners (0-3%)
- Increased risk for sexual HCV transmission:
  - Having a sexually transmitted disease (STD)
  - Having HIV infection
  - Multiple sexual partners
  - Rough sex
- Risk does <u>not</u> appear higher among HIV-negative men who have sex with men (MSM)



Source: Centers for Disease Control and Prevention. Viral Hepatitis Information for Gay and Bisexual Men. 2014.


### **Hepatitis = "Inflammation of the Liver"**



- Possible complications of hepatitis C infection:
  - Severe fatigue
  - Ascites (accumulation of fluid in the abdomen)
  - Encephalopathy (confusion due to buildup of ammonia in brain)
  - End stage liver disease (decompensated cirrhosis)
  - Hepatocellular carcinoma (liver cancer), fatal without a transplant




### Natural History of HCV over 10-25 Years





## Chronic Hepatitis C – Rates of Newly Reported Cases by County, Excluding Cases in State Prisons, California, 2011 and 2015






<sup>\*</sup> No cases reported or statistically unstable rates for five local health jurisdictions in 2011, including Alpine, Colusa, Inyo, Mono, and Sierra counties; and two local health jurisdictions in 2015, including Alpine and Sierra counties.

<sup>·</sup> State prisons cases were removed from local health jurisdiction totals and attributed to the state prison system as a whole.




# Cases and Percentages of Chronic HCV Cases by Race/Ethnicity, California, 2011-2015






Key: **W=White**, H/L=Hispanic/Latino, **AA/B=African American/Black**, API=Asian/Pacific Islander, **AI/AN=American Indian/Alaska Native** 

### Chronic Hepatitis C – Age Distribution of Newly Reported Cases, California, 2007 and 2015






\*N = 41,037; excludes 547 cases with missing age or sex information.

†N = 33,454; excludes 294 cases with missing age or sex information.




# Increasing Rates of Newly Reported Chronic Hepatitis C Cases in Persons Ages 15-29—California, 2011-2015



# Hepatitis C and Opioid Injection Increasing at Similar Rates

# HEPATITIS C AND OPIOID INJECTION ROSE DRAMATICALLY IN YOUNGER AMERICANS FROM 2004-2014



 Among people aged 18-29, HCV increased by 400% and admission for opioid injection by 622%

MAT maintenance reduces HCV incidence among young people who inject drugs by 50%





# Role of Hubs & Spokes in reducing the hepatitis C disease burden

Prevention

Education

Testing & Linkage to Care

Treatment



# Ensure People Receive <u>Both</u> Steps in the HCV Testing Process

#### 1) Screen for HCV antibody (anti-HCV)

- Rapid finger-stick test or blood draw
- o "Have you ever had hepatitis C?"
- o Expect ≥15-20% HCV positivity in NTPs

#### 2) If reactive, test for HCV nucleic acid \*

- o Blood draw only
- o "Do you have hepatitis C virus in your blood now?"
- On-site phlebotomy recommended



\* Also called ribonucleic acid (RNA) test; polymerase chain reaction (PCR) test, viral load test; quantitative or qualitative.

# Medi-Cal Billing (CPT) Codes for Hepatitis C Virus (HCV) Testing

Test	CPT Code	Rate
HCV antibody	86803	\$12.57
HCV RNA	85720	\$21.83
	87521	\$38.21
	87522	\$38.68

Key: CPT=Current Procedural Terminology; RNA = ribonucleic acid, a test needed to detect current infection

### **Post-Diagnostic Laboratory Testing**

#### Viral Load

- Can be in the billions
- Not predictive of HCV progression or liver health
- Used to monitor response to HCV treatment

#### Genotype

- Six genotypes; 74% HCV+ in U.S. have genotype 1
- Can be used to determining best course of treatment although newer drugs are "pangenotypic," meaning they work on all HCV genotypes

#### Tests for coinfection

- Hepatitis A, hepatitis B, HIV
- Liver function/health
  - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), etc.



Source: <a href="http://www.hepatitisc.uw.edu/">http://www.hepatitisc.uw.edu/</a>

### **Staging of Liver Disease**


- Classification of liver scarring (1-4)
  - 1=Minimal; 2=Mild; 3=Moderate; 4=Severe
- Indirect markers of fibrosis
  - Aspartate Aminotransferase-to-Platelet ratio index (APRI), FIB-4, FibroSure, Fibroscan, etc.
  - Used to determine presence of cirrhosis
  - Less useful for determining stage of fibrosis
- Ultrasound transient elastography
- Liver biopsy (gold standard but not needed)



Source: <a href="http://www.hepatitisc.uw.edu/">http://www.hepatitisc.uw.edu/</a>

# Living with Hep C? New treatments have changed the game

Direct-Acting Antivirals!



There is new hope for people with Hep C Come visit us to talk about the new cure


Glide Harm Reduction Program - 5th floor 330 Ellis Street (between Taylor & Jones) San Francisco, CA 94102 (415) 674-5188 / hepc@glide.org For more info, visit www.endhepcsf.org







# Hepatitis C Can Be CURED in 8-12 Weeks



# DHCS HCV Treatment Guidelines, July 2015


HCV treatment is covered for people with...

- Evidence of liver disease:
  - Stage 2 or higher fibrosis, serious extrahepatic manifestations, liver cancer or post liver transplant
- Comorbidities:
  - HIV, HBV, liver disease, diabetes, debilitating fatigue
- Likelihood of transmitting HCV to others:
  - Men who have sex with men and have high risk sexual practices,
     active injection drug users, women of childbearing age who wish to get pregnant, health care workers who perform exposure prone procedures, people on hemodialysis



Source: http://www.dhcs.ca.gov/Pages/HepatitisC.aspx

# MAT Plus HCV Treatment and Syringe Access Can End Hep C



Median prevalence in 2015: 56.0%

With no intervention prevalence 83.0% in 2030.

50% MAT+SSP (Full HR): increase in prevalence slowed but not stopped.

Full HR + HCV-treat 20/1000 PWID annually stabilises prevalence

Full HR + HCV-treat 50/1000 PWID annually decreases prevalence by 15% by 2030.

- No intervention scale-up
- Full HR + HCV-treat 20/1000 PWID annually
- - 50% SSP & 50% MAT (Full HR) - Full HR + HCV-treat 50/1000 PWID annually

Median projections for a sample of 1000 parameter sets.

Source: Vickerman P et al., Impact and cost-effectiveness of scaling up HCV treatment and prevention interventions for PWID in the U.S. University of Bristol; 2017.

Key: MAT = medication assisted treatment; SSP = syringe services program; HR = harm reduction.

### Summary

- Hepatitis C rates are increasing among young adults in California
- MAT can reduce HCV incidence in young people who inject drugs by 50%!
- All people who have ever injected drugs should be tested for hepatitis C
- Testing is a 2-step process: Antibody + RNA
- New treatments have changed the game and people on MAT can be cured of HCV!
- CDPH
  California Department of
  Public Health

H&S sites have a critical role in ending hep C

#### **Contact Information**

Rachel McLean, MPH

Chief, Office of Viral Hepatitis Prevention

STD Control Branch

California Department of Public Health

Phone: (510) 620-3403

Email: Rachel.McLean@cdph.ca.gov

Website: <a href="https://www.cdph.ca.gov/ovhp">www.cdph.ca.gov/ovhp</a>



#### **CME EVALUATION**

https://www.surveymonkey.com/r/XCF6K7V

<u>Psychologist Counselor CE Evaluation Link</u> <u>https://www.surveymonkey.com/r/XHGB876</u>

<u>LMFT/LCSW/SUD Counselor CE Course</u> <u>https://www.surveymonkey.com/r/XHGB876</u>

Further Questions/Concerns please contact pflippinweston@mednet.ucla.edu





